Our findings therefore suggest that therapeutic interventions are likely to work best in childhood-onset ABCA4-associated retinopathy if given very early, although it may be challenging to recruit such patients for clinical trials until convincing safety and efficacy data are available in adults. Here, ABCA4 is linked to retinal disorder.